Top Read Articles

Published in last 1 year |  In last 2 years |  In last 3 years |  All

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 1-13.   Abstract （54）      PDF （1944KB）（62）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Study on the development trend of liver cancer mortality among Chinese residents from 2012 to 2021 Shao Tang, Zheng Fangshu, Wu Jun Electronic Journal of Liver Tumor    2024, 11 (3): 54-57.   Abstract （35）      PDF （1992KB）（9）       Knowledge map    Save Objective: To analyze the trends of liver cancer mortality and standardized mortality among Chinese residents from 2012 to 2021. Methods: The trend of liver cancer mortality and standardized mortality among Chinese residents was studied and analyzed by using the Joinpoint regression model with the number of liver cancer deaths and survey population in the National Disease Surveillance System Cause of Death Surveillance Dataset (2012), the Chinese Cause of Death Surveillance Dataset (2013-2021), and the data from the 6th and 7th national census as the study data. Results: The number of liver cancer deaths and mortality rates among men in the surveillance population from 2012 to 2021 years were approximately 2.7 to 2.8 times higher than those among women. There were 2 Joinpoint turning points for liver cancer mortality in the total, male and female populations in the surveillance population from 2012 to 2021 years, with the turning points in the male population occurring in 2014 years and 2018 years, with an increasing trend from 2012 to 2014 years (P<0.05) and a decreasing trend from 2014 to 2018 years (P<0.05). The turning points in the total and female populations occurred in 2014 years and 2019 years, with an upward trend from 2012 to 2014 years (P<0.05) and a downward trend from 2014 to 2019 years (P<0.05). There was one Joinpoint turning point of liver cancer mortality in the total population, male population and female population, which occurred in 2019 years, and the female population showed an increasing trend from 2019 to 2021 years (P<0.05). Conclusion: The mortality rate of liver cancer in the monitored population was higher in males than in females, and its development trend showed an increasing trend before 2014 and a decreasing trend after 2014, and the trend of the standardized mortality rate of liver cancer tended to be stable. Reference | Related Articles | Metrics

Select

From susceptibility to prognosis: the multifaceted role of the cytochrome p450 family in hepatocellular carcinoma Hong Shengjie, Zhang Guangquan, Li Ruixi, He Yongfei, Wu Fenfang, Shi Xianjie Electronic Journal of Liver Tumor    2024, 11 (3): 58-63.   Abstract （33）      PDF （2799KB）（6）       Knowledge map    Save The cytochrome P450 (CYP450) family is a group of enzymes that play a crucial role in the metabolism of exogenous and endogenous compounds. Growing evidence suggests that the CYP450 family is pivotal in the occurrence, progression, and prognosis of hepatocellular carcinoma (HCC). Polymorphisms in CYP450 family genes can influence an individual's susceptibility to carcinogens and metabolic capacity, closely associated with the risk of HCC. Furthermore, dysregulation of CYP450 family genes is involved in HCC progression, with mechanisms encompassing reactive oxygen species levels, DNA damage, cell proliferation, invasion, and apoptosis. The expression levels of CYP450 family genes are also intimately linked to the prognosis of HCC patients, showing promise as essential indicators for prognostic assessment. In conclusion, a deep understanding of the role of the CYP450 family in the occurrence, progression, and prognosis of HCC is of great significance for elucidating the molecular mechanisms of HCC and developing individualized prevention and treatment strategies. Future research should further investigate the molecular mechanisms underlying the polymorphisms and dysregulation of CYP450 family genes, establish corresponding risk prediction and prognostic evaluation models, and emphasize the regulatory effects of drugs on the CYP450 family, aiming to provide new strategies and targets for the prevention and treatment of HCC. Reference | Related Articles | Metrics

Select

A new strategy for solid tumor treatment: the immunotherapeutic potential of chimeric antigen receptor macrophages Kong Qinghao, Li Shuang, Lu Yinying Electronic Journal of Liver Tumor    2024, 11 (3): 16-19.   Abstract （32）      PDF （1898KB）（8）       Knowledge map    Save Solid tumors are one of the major diseases threatening human health worldwide. Traditional treatments such as surgery, radiotherapy, and chemotherapy have their inherent limitations, and although immune checkpoint inhibitors have shown efficacy, not all patients respond to them. Chimeric antigen receptor-macrophage (CAR-M) therapy involves the genetic engineering of macrophages to express chimeric receptors that specifically recognize tumor antigens, demonstrating the potential for targeted tumor cell destruction. However, CAR-M therapy for solid tumors is currently in the preclinical and early clinical research stages. This paper provides a comprehensive review of the current state of preclinical studies on CAR-M, including the design of CAR structures, sources of donor cells, and vectors for delivering CAR genes to macrophages. Additionally, it summarizes the limitations and challenges faced in the development of CAR-M, offering new research perspectives for the future advancement of CAR-M therapy. Reference | Related Articles | Metrics

Select

Preliminary observe of the efficacy and safety of mixed liver cancer immunotherapy Liang Jun, Yang Zhenyun, Zhang Yaojun, Chen Minshan, Hu Dandan Electronic Journal of Liver Tumor    2024, 11 (3): 20-24.   Abstract （29）      PDF （2247KB）（6）       Knowledge map    Save Objective: To observe preliminary the efficacy and safety of immune checkpoint inhibitors in the treatment of mixed liver cancer. Methods: From January 2018 to December 2023, clinical data of patients admitted to the Cancer Prevention Center of Sun Yat-sen University were collected, including basic information, treatment plan, laboratory indicators and survival status. Efficacy was assessed by response evaluation criteria in solid tumors v1.1 for solid tumors. The survival analysis with Kaplan-Meier curve. The univariate and multivariate analysis with Cox regression model. Results: A total of 21 patients with mixed liver cancer were collected. The median age was 55 years. The objective response rate was 28.6%. The disease control rate was 52.4%. The median progression-free survival time was 12.4 months (95%CI : 6.7-18.1 months). The median overall survival time was 14.4 months (95%CI: 10.4-18.4 months). Multivariate analysis showed that cancer thrombus (HR=3.95, 95%CI: 1.09-14.28, P=0.036) and increased carcinoembryonic antigen levels (>5 μg/L) (HR=5.46, 95%CI: 1.14-26.17, P=0.034) were associated with poor progression-free survival time. Adverse events of any level were controllable and no adverse event-related deaths. Conclusion: Preliminary observe shows that the immune checkpoint inhibitors have good efficacy and safety in the treatment of mixed liver cancer, and the increased thrombus and increased antigen level (> 5 μg/L) may be adverse factors to shorten the progression-free survival time. Reference | Related Articles | Metrics

Select

Expression and clinical significance of transmembrane protein 132A in liver cancer based on bioinformatics Zhao Hangqi, Ma Xiaowen, Zhang Tian'ai, Li Baifeng Electronic Journal of Liver Tumor    2024, 11 (3): 33-41.   Abstract （24）      PDF （9212KB）（13）       Knowledge map    Save Objective: To explore the expression pattern and clinical significance of transmembrane protein 132A (TMEM132A) in liver cancer based on public databases. Methods: The Cancer Genome Atlas and GSE14520, GSE60502 of Gene Expression Omnibus was used to analyze the mRNA level of TMEM132A in liver cancer and adjacent tissues, the promoter methylation level, and the correlation with clinical factors. The immunohistochemical results of TMEM132A in tissues were obtained through HPA database. Kaplan-Meier method was used to explore the correlation between TMEM132A and the prognosis of patients. Receiver operating characteristic curve was used to explore whether TMEM132A could accurately diagnose patients. The drug sensitivity of TMEM132A to chemotherapy drugs was predicted by cancer drug sensitivity genomics. Immune analysis of TEME132A was performed by single-sample GSEA, TIMER, STORMAL SCORE and immune checkpoint heatmap. Linkedomics website was used to perform gene set enrichment analysis for differential genes of TMEM132A. The STRING database was used to predict the interacting proteins of TMEM132A. Results: The expression of MEM132A in HCC tissues was significantly higher than that in adjacent tissues (P<0.05), and it was located in the cytoplasm and cell membrane. The high expression of TMEM132A was positively correlated with tumor stage, grade, AFP level and body weight. High expression of TMEM132A indicates poor prognosis and can be used as an accurate diagnostic indicator. TMEM132A is sensitive to a variety of chemotherapy drugs and infiltrated by a variety of immune cells, which can be used as a research target for drug therapy and immunotherapy. The promoter methylation level of TMEM132 was significantly decreased in cancer tissues. TMEM132A affects cell adhesion, fatty acid metabolism and other signaling pathways. Conclusion: TMEM132A is highly expressed in HCC and positively correlated with poor prognosis. Reference | Related Articles | Metrics

Select

Clinical features and prognosis analysis of combined mixed hepatocellular carcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: propensity match analysis Zhu Runze, Mu Shaowei, Li Zhao, Zhu Jiye, Gao Jie Electronic Journal of Liver Tumor    2024, 11 (3): 25-32.   Abstract （23）      PDF （2576KB）（12）       Knowledge map    Save Objective: To compare the clinicopathological features and prognosis of mixed hepatocellular carcinoma (mHCC), hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) after surgical resection. Methods: The clinical data of 317 patients diagnosed with liver malignant tumors who were admitted to the Department of Hepatobiliary Surgery, Peking University People's Hospital from January 2015 to December 2023 were retrospectively analyzed. After propensity matching with 1:1 in the degree of tumor differentiation, lymph node metastasis and AJCC (8th edition) stage, 150 patients were enrolled in two independent matching cohorts: mHCC and HCC 43 cases each, mHCC and ICC 32 cases each. The clinical characteristics and prognosis of patients were compared between groups. Normally distributed continuous variables were compared using Student's t-test or one-way ANOVA, and non-normally distributed continuous variables were compared using Wilcoxon rank sum statistics. Chi-square test is used to compare categorical variables. The Kaplan-Meier method assesses median survival and median disease-free survival. Results: The age, sex, and degree of cirrhosis of mHCC patients were similar to those of HCC and ICC patients, and the prevalence of hepatitis B was lower than that of HCC patients but comparable to that of ICC patients. mHCC patients had significantly higher levels of AFP than those of ICC patients, lower levels of CA19-9 than those of HCC patients, and significantly higher levels of CEA than those of the other two pathological types. mHCC's pathological features of microvascular invasion rate and lymph node metastasis rate were higher than those of HCC and comparable to those of ICC.The median survival of mHCC patients was worse than that of HCC patients (19.6 months vs. 70.8 months, P<0.001) and comparable to that of ICC patients (19.6 months vs. 40.6 months, P=0.07). mHCC patients had a worse disease-free survival than that of HCC patients and comparable to that of ICC patients. Multifactorial Cox analysis showed that lymph node metastasis, poorly differentiated tumor, tumor stage, pathological type and history of alcohol consumption were independent risk factors associated with prognosis, and that poorly differentiated tumor and tumor stage were independent risk factors for disease-free survival; multiple tumors were an independent risk factor affecting postoperative prognosis in both 1:1 matched cohorts. Conclusions: The clinical features and prognosis of mHCC are not consistent with those of HCC and ICC, and it is a rare pathological type with a high degree of malignancy that is highly susceptible to recurrence, and it should be treated as a unique tumor type in primary hepatocellular carcinoma. The mHCC has a poorer long-term survival than HCC, and it is comparable to that of ICC, and lymph node metastasis, poorly differentiated tumors, tumor stage, and a history of alcohol consumption are prognostically relevant independent risk factors, luminal surgery was a prognostically relevant independent insurance factor, and poorly differentiated tumors and tumor stage were independent risk factors for disease-free survival. The multiple tumors were found to be associated with poor prognosis and recurrent metastases in mHCC after propensity matching. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 64-67.   Abstract （20）      PDF （3734KB）（6）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Intraoperative use of dexmedetomidine in patients with hepatocellular carcinoma: prognostic impact and mechanism analysis Shao Chaoyan, Ma Zhonglin, Wu Wei, Wu Song, Zheng Lidong Electronic Journal of Liver Tumor    2024, 11 (3): 42-53.   Abstract （18）      PDF （17371KB）（9）       Knowledge map    Save Objective: The aim is to investigate the impact of intraoperative dexmedetomidine (DEX) on the prognosis of patients with hepatocellular carcinoma (HCC) and to investigate the underlying mechanisms. Methods: Retrospective analysis of clinical data of 144 HCC patients undergoing hepatectomy in Lu’an Hospital of Anhui Medical University from January 2019 to January 2023. The association between DEX and the prognosis of HCC patients was determined by univariate and multifactorial Cox risk regression. To resolve DEX cancer-promoting mechanisms by bioinformatics, western blotting, immunohistochemistry and various online databases. Results: 144 patients were followed up for 6-48 months with a mean follow-up time of 32.9 months, including 63 recurred and 57 patients died. Patients with intraoperative DEX had lower recurrence-free survival (P<0.05) and overall survival (P<0.05) than those without DEX. Univariate combined with multifactorial Cox risk regression analysis identified intraoperative DEX use as an independent risk factor for recurrence and death in HCC patients (P<0.05). Six DEX-regulated genes were identified based on the GSE188867 dataset and the TCGA-HCC cohort: CCDC34, E2F8, CENPH, CTHRC1, CENPW, and E2F1. Western blotting and IHC results showed that E2F8 and E2F1 expression was increased in HCC tissues (P<0.05) and was rapidly upregulated by DEX (P<0.05). Computerized molecular docking models showed that DEX stably formed hydrogen bonds with ARC-267 and LYS-264 residues in E2F8 at a binding energy of -6.7 kcal/mol and with TYR-746 residues in E2F1 at an energy of -5.0 kcal/mol. The results of gene set enrichment analysis (GSEA) highlighted that DEX could rapidly activate cell cycle signaling (P<0.05). Conclusion: Intraoperative systemic administration of DEX mediates a worse prognosis in patients with HCC, a process that involves DEX's rapid activation of cell cycle signaling, including possible direct binding to E2F8 and E2F1. DEX should be used with caution in patients with HCC. Reference | Related Articles | Metrics

Select

A network calculator based on lymphocyte ratio-associated immune-inflammatory response score predicts survival in patients with hepatocellular carcinoma Shi Limin, Zhang Mingxing, Cai Siqi, Yang Yueyi, Yang Chunyi, Zhang Wenqiong Electronic Journal of Liver Tumor    2024, 11 (4): 19-26.   Abstract （18）      PDF （7030KB）（7）       Knowledge map    Save Objective: To develop a lymphocyte ratio-associated immune-inflammatory response score (IRS) and construct a network calculator to predict prognostic risk in patients with hepatocellular carcinoma (HCC). Method: HCC patients who were surgically treated in Shanghai Public Health Clinical Center between January 2018 and December 2023 were selected. Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR) and C-reactive protein to lymphocyte ratio (CLR) were collected. IRS was constructed using multifactorial Cox risk regression. Univariate and multifactorial Cox regression models were used to analyse risk factors for mortality in HCC patients. Constructed and assessed nomogram prediction accuracy using R packages such as rms, foreign, readxl, Hmisc and rmda. Development of a mortality risk network calculator for HCC patients using the DynNom package. Result: 154 patients were followed up from 1 month to 60 months, with a median follow-up of 17 months, in which the 1-, 3- and 5-year mortality rates were 30.5%, 50.6% and 61.0%, respectively. IRS=0.213 × NLR+0.005×PLR+0.042×CLR was constructed based on the multifactorial Cox risk regression coefficient β. IRS was significantly higher in patients who died than in those who survived (P<0.05). Patients in the high-risk group (IRS≥2.88) had significantly lower survival than patients in the low-risk group (IRS<2.88) (P<0.05). Time- receiver operating characteristic (ROC) curves showed areas under the curve (AUCs) of 0.829 (95% confidence interval [95%CI]: 0.760-0.885), 0.901 (95%CI: 0.842-0.943), and 0.898 (95%CI: 0.839-0.941) for 1-year, 3-year, and 5-year risk of death among patients with IRS prediction, respectively. The results of multifactorial Cox risk regression analysis showed that maximum tumour diameter, γ-glutamyl transferase (GGT), alkaline phosphatase (ALP), alpha-fetoprotein (AFP) and IRS were independent factors for the risk of death in HCC patients (P<0.05). Nomogram were constructed based on IRS to predict the risk of death in HCC patients at 1, 3 and 5 years. The calibration curves showed that the C-index of the nomogram predicting the risk of death at 1, 3 and 5 years was 0.836 (95%CI: 0.818-0.912), 0.903 (95%CI: 0.882-0.961) and 0.847 (95%CI: 0.817-0.932), respectively, respectively, and time-decision curve analysis (DCA) revealed that the nomogram provided a significant meaningful clinical net benefit for risk thresholds in the range of 0-1. The web calculator interface is available at https://nomogramdynamic.shinyapps.io/DynNomapp/. Conclusion: The risk of death in HCC patients can be effectively predicted by evaluating and localising the IRS. The network calculator of the risk of death in HCC patients constructed by the IRS combined with the maximum diameter of the tumour, GGT, ALP, and AFP can provide a more positive basis for the treatment of patients with a poorer prognosis. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 68-71.   Abstract （17）      PDF （3464KB）（6）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 72-76.   Abstract （15）      PDF （7192KB）（2）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 14-15.   Abstract （15）      PDF （1553KB）（9）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Exploration of the guiding significance of protein regulating cytokinesis 1 in the management of gastrointestinal tumors Liu Yifeng, Ran Yihong, Che Xu Electronic Journal of Liver Tumor    2024, 11 (4): 27-35.   Abstract （15）      PDF （3724KB）（1）       Knowledge map    Save Objective: Analyzing the expression, biological role, and prognostic impact of protein regulating cytokinesis 1 (PRC1) in gastrointestinal tumors through bioinformatics tools, and subsequently guide clinical treatment. Method: Based on a public database analysis, the expression level of PRC1 in gastrointestinal tumors, co-expressed genes, biological mechanisms of action, immunological regulatory characteristics, interpretation of gene mutation sites, prognostic impact on various tumors, and the prognostic impact of gene mutations on gastrointestinal tumors are analyzed. Result: PRC1 was highly expressed in cholangiocarcinoma, colon cancer, liver cancer, pancreatic cancer, rectal cancer, and gastric cancer, and highly co-expressed with PRC1 related genes, which together affected the biological process of gastrointestinal tumors. The PRC1 and related gene sets were mainly enriched in mitotic related items in gene ontology (GO) enrichment analysis. In terms of immune promotion, PRC1 plays a regulatory role in B, CD4+, CD8+ and other immune cells in gastric and pancreatic cancer. PRC1 affects the biological process of gastrointestinal tumors in various forms of deep deletion, shallow deletion, diploid mutation, and amplification. The main mutation forms of each point on the PRC1 segment are missense mutations and truncations, which affect the translation and expression of PRC1, thereby affecting the biological process of gastrointestinal tumors. The high expression of PRC1 affects the prognosis of gastric cancer and pancreatic cancer. PRC1 mutation group indicates a poor prognosis of gastrointestinal tumors. Conclusion: The high expression and mutation of PRC1 in gastrointestinal tumors are high-risk factors for malignant progression and poor prognosis of gastrointestinal tumors, further guiding clinical treatment strategies. Reference | Related Articles | Metrics

Select

Combination therapy with TIGIT monoclonal antibody in the first-line treatment of advanced hepatocellular carcinoma: a commentary based on the results of two phase-Ⅱ clinical studies Jiang Ning, Li Xuchu, Huang Huiyao, Sun Chao, Fang Hong, Ma Hailan, Jia Shuopeng, Wu Dawei, Tang Yu, Li Ning Electronic Journal of Liver Tumor    2024, 11 (4): 6-12.   Abstract （15）      PDF （2958KB）（11）       Knowledge map    Save Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer worldwide. Despite significant progress in the early diagnosis and treatment of HCC in recent years, the prognosis for patients with advanced HCC remains poor. Emerging immunotherapies for HCC, such as programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, have demonstrated some clinical efficacy, but issues with resistance persist. Monoclonal antibodies targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), as a novel immune checkpoint inhibitor, have the potential to enhance anti-tumor immune responses when used in combination with PD-1/PD-L1 inhibitors. This article, based primarily on the results of the AdvanTIG-206 and MORPHEUS-Liver Phase II clinical trials, summarizes the current efficacy and safety of TIGIT monoclonal antibody combination therapy as a first-line treatment for patients with advanced HCC. Additionally, it explores the potential and possible challenges of combining TIGIT antibodies with PD-1/PD-L1 inhibitors and targeted therapies, with the aim of identifying new directions for first-line therapy in advanced HCC. Reference | Related Articles | Metrics

Select

Research progress of locoregional therapies combined with systemic therapies in unresectable hepatocellular carcinoma Jing Congmin, Zhang Yubao Electronic Journal of Liver Tumor    2024, 11 (4): 50-53.   Abstract （15）      PDF （1534KB）（6）       Knowledge map    Save Liver cancer ranks fifth in the incidence of malignant tumors and second in the causes of cancer-related death in China. Most of the patients have already developed to the middle and late stages when characteristic symptoms appear, have missed the best time for surgery, so palliative therapy plays a central role in the treatment of hepatocellular carcinoma. Locoregional treatment is one of the main therapeutic options for patients with unresectable hepatocellular carcinoma (uHCC), and immunotherapy and targeted systemic therapy have also made substantial progress in recent years, but the effect of interventional therapy alone or monotherapy is limited. Several combination therapy options have been actively explored in clinical studies, with encouraging efficacy and brought hope for the treatment of uHCC patients. Among them,the new combination of locoregional combined with systemic therapy is expected to be a potential therapeutic modality for intermediate and advanced hepatocellular carcinoma. This review provides an overview of the current status of research on locoregional combined with systemic therapy, aim to provide more treatment strategies for uHCC patients. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (4): 63-66.   Abstract （14）      PDF （1701KB）（11）       Knowledge map    Save Related Articles | Metrics

Select

The application value of contrast-enhanced ultrasound on the differentiation of colorectal cancer liver metastasis and atypical hepatic hemangioma Chen Yuxiang, Yan Ji, Zhang Chenxue, Yu Haitao, Wu Xueliang, Wang Likun Electronic Journal of Liver Tumor    2024, 11 (4): 36-41.   Abstract （14）      PDF （3622KB）（2）       Knowledge map    Save Objective: To explore the clinical application value of contrast-enhanced ultrasound (CEUS) in differentiating between colorectal cancer liver metastasis (CCLM) and atypical hepatic hemangioma (AHH). Method: A retrospective analysis was conducted on patients diagnosed with 76 cases of CCLM and 80 cases of AHH between 2020 and 2022, who underwent CEUS and received pathological confirmation at our institution. The ultrasonographic characteristics of both groups were compared. The diagnostic sensitivity, specificity, accuracy, and receiver operating characteristic (ROC) curves were analyzed for conventional ultrasound alone and in combination with CEUS. Result: The results indicated significant differences in ultrasound enhancement features between CCLM and AHH, with statistically significant differences in tumor lesion internal and surrounding blood flow signals (P<0.05). Conventional ultrasound combination with CEUS significantly improved the specificity and accuracy in diagnosing CCLM compared to conventional ultrasound alone. Furthermore, the area under the curve for conventional ultrasound combination with CEUS was significantly higher than that for conventional ultrasound. Conclusion: CEUS is an effective method for enhancing the ultrasound differentiation capability between CCLM and AHH. Reference | Related Articles | Metrics

Select

Progress summary clinical trials of new drugs for liver cancer Sun Jiayang, Hu Wei, Tang Yu Electronic Journal of Liver Tumor    2024, 11 (4): 1-5.   Abstract （14）      PDF （1948KB）（15）       Knowledge map    Save Objective: To summarize the development trend of global clinical trials of primary hepatic cancer(HCC) from 2020 to June 2024. Methods: Based on the Trialtrove database developed by Informa Pharma Intelligence (London, UK), the clinical trials of liver cancer and the related medicines launched from 2020 to 2024 were extracted. The annual growth rate, the characteristics of trials and tested products were analyzed. Results: During the statistical period, a total of 356 clinical trials for HCC were carried out worldwide, accounting for 4.3% of all anti-cancer clinical trials. Among them, 189 (53.1%) were initiated by domestic companies. The number of clinical trials for HCC peaked in 2022 (101 trials). Phase I(including phase Ⅰ/Ⅱ) clinical trials were the most common trial phase type (266 trials, 74.7%). In terms of trial indications, drug development for advanced HCC accounted for the highest proportion (324 trials, 91.0%). Among all the investigational drugs, the types of drugs involved mainly included antibody drugs (48.0%), small molecule targeted drugs (25.4%), cell and gene therapy (15.4%) and antibody-drug conjugate (5.0%). Thirty-two clinical trials focused on first line treatment for late-stage HCC. Among them, the main investigational treatment modality was combined immunotherapy based on immune checkpoint inhibitors. A total of 262 clinical trials were conducted for patients with advanced HCC progressed after previous treatment, of which 32 trials (12.2%) were carried out in patients failed immunotherapy. All the 32 trials were in phase Ⅰ/Ⅱ trials, involving a variety of experimental drug types. Conclusions: The clinical development of liver cancer drugs is active in the world, and domestic enterprises play an important role. In liver cancer, immunotherapy is the most active field of drug development. While in the clinical trials including heavily treated HCC patients, cell and gene therapy is also an important clinical research area. It is suggested that domestic enterprises should increase investment in the development of novel drugs for liver cancer, explore more new targets and drugs with new mechanisms, and broaden the possible directions of liver cancer treatment. Reference | Related Articles | Metrics

Select

Research progress on hand-foot skin reaction in targeted therapy for hepatocellular carcinoma Ning Yanting, Xia Juan, Wu Shu, Zhang Qi, Li Xiaoqing, Che Xu, Zhan Zhengyin Electronic Journal of Liver Tumor    2024, 11 (4): 54-59.   Abstract （13）      PDF （1822KB）（3）       Knowledge map    Save Targeted drugs, as an important means in the treatment of liver cancer, have significantly improved the overall survival rate of liver cancer patients. However, some side effects inevitably occur during treatment. Hand-foot skin reaction is one of the common adverse reactions, which not only affects the patient's quality of life, but may also force the patient to reduce the dosage of the drug or interrupt treatment. , thus affecting the therapeutic effect. This article comprehensively analyzes the current research status of hand-foot skin reactions related to targeted drugs at home and abroad, discusses its pathogenesis, clinical manifestations, and grading standards, and compares the differences in chemotherapy-related hand-foot syndrome. In addition, this article also focuses on the prevention and care strategies, health education, traditional Chinese and Western medicine treatments for hand-foot skin reactions, etc, aiming to reduce patients' symptoms, improve their quality of life, and improve their treatment compliance. At the same time, the existing problems and future development trends of hand-foot skin reactions in liver cancer targeted therapy are summarized, with a view to providing a comprehensive reference basis for clinicians and nursing workers, and for the prevention and management of hand-foot skin reactions related to liver cancer targeted drug treatment. Reference | Related Articles | Metrics